سابِق|تال

Clinical study of Quxie Capsule combined with fruquintinib in the treatment of metastatic colorectal cancer and prolonging third-line survival

  • role： First author第一作者
  • Affiliation：

    Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

  • Introduction：边江昱，女，在读硕士生
BIAN Jiangyu1,  
  • Affiliation：

    Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine, Urumqi 830000, China

HE Wenting2,  
  • Affiliation：

    Guang′anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China

WANG Xueqian3,  
  • Affiliation：

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China

LIU Chuanbo4,  
  • Affiliation：

    Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

CAI Linlin1,  
  • Affiliation：

    Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

XU Yun1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

  • Email：ashtray7654@126.com
  • Introduction：ZHANG Tong, Ph.D., Associate Chief Physician, Master′s Supervisor. Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, No.1, Xiyuan Playground, Haidian District, Beijing 100091. E-mail: ashtray7654@126.com
ZHANG Tong1*

ملخص

ObjectiveTo observe the clinical efficacy of Quxie Capsule combined with fruquintinib in the treatment of metastatic colorectal cancer (mCRC).MethodsA prospective, non-randomized, controlled study was used to collect patients with mCRC who planned to receive third-line treatment after second-line treatment at Xiyuan Hospital of China Academy of Chinese Medical Sciences, Guang′anmen Hospital of China Academy of Chinese Medical Sciences, Dongfang Hospital Beijing University of Chinese Medicine, and Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine. The treatment group received Quxie Capsule combined with fruquintinib. The control group was treated with fruquintinib. The primary outcome measure was third-line overall survival (OS), and the secondary outcome measure was third-line progression-free survival (PFS).ResultsA total of 142 patients with mCRC were included in this study (79 in the treatment group and 63 in the control group). The median OS(mOS) was 19.0 months in the treatment group and 8.1 months in the control group, and the difference was statistically significant [HR = 0.285, 95% CI (0.183, 0.436), P < 0.001]. The median PFS(mPFS) in the treatment group was 7 months, mPFS in the control group was 2 months, and the difference was statistically significant [HR = 0.248, 95% CI (0.165, 0.362), P < 0.001]. In subgroups, such as age, gender, primary site, peritoneal metastasis, and genotype, mOS in the treatment group was longer than in the control group (P < 0.001). Multivariate COX proportional hazard model analysis showed that peritoneal metastasis was an independent prognostic factor and the risk of death increased 2.14 times. The combination with Quxie Capsule was a protective factor, reducing the risk of death by 76.8%.ConclusionThe Quxie Capsule combined with fruquintinib can prolong mOS survival and mPFS of mCRC treated in the third-line stage.

مفهوم

Quxie Capsule;fruquintinib;metastatic colorectal cancer;third-line treatment;Yinyang Gongji Pill;method of warming yang and dredging intestines

References

  1. [1].
    DEKKER E, TANIS PJ, VLEUGELS JLA, et al.Colorectal cancer[J]. Lancet, 2019，394(10207)：1467-1480.
  2. [2].
    BENSON AB, VENOOK AP, AL-HAWARY MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021，19(3)：329-359.
  3. [3].
    CERVANTES A, ADAM R, ROSELLÓ S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(1): 10-32.
  4. [4].
    MI M, WENG SS, XU ZH, et al. CSCO guidelines for colorectal cancer version 2023: updates and insights[J]. Chin J Cancer Res，2023，35(3): 233-238.
  5. [5].
    LI J, QIN S, XU RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer[J]. JAMA，2018, 319(24): 2486.
  6. [6].
    DASARI A, LONARDI S, GARCIA-CARBONERO R, et al.Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study[J].Lancet，2023，402(10395)：41-53.
  7. [7].
    XU J, XU RH, QIN S, et al. Regorafenib in Chinese patients with metastatic colorectal cancer: subgroup analysis of the phase 3 CONCUR trial[J]. J Gastroenterol Hepatol，2020，35(8)：1307-1316.
  8. [8].
    GROTHEY A, VAN CUTSEM E, SOBRERO A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet，2013，381(9863)：303-312.
  9. [9].
    XU JM, KIM TW, SHEN L, et al. Results of a randomized, double-blind, placebo-controlled, phase Ⅲ trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study[J]. J Clin Oncol, 2018, 36(4): 350-358.
  10. [10].
    PRAGER GW, TAIEB J, FAKIH M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer[J]. N Engl J Med, 2023, 388(18): 1657-1667.
  11. [11].
    张彤，何文婷，陈悦，等. 中西医结合治疗对晚期结直肠癌患者生存影响的队列研究[J]. 北京中医药大学学报，2023, 46(3): 383-391.
  12. [12].
    ZHANG T, HE WT, ZI MJ, et al. Cohort study on prognosis of patients with metastatic colorectal cancer treated with integrated Chinese and western medicine[J]. Chin J Integr Med, 2018, 24(8): 573-578.
  13. [13].
    孙凌云，闫蕴孜，徐钰莹，等. 基于单中心回顾性真实世界研究的晚期结直肠癌三线中西医结合治疗现状及疗效分析[J]. 中医肿瘤学杂志，2022, 4(1): 18-23.
  14. [14].
    杨宇飞，王建彬. 通阳法防治结直肠癌的理论探析[J]. 浙江中医药大学学报，2009, 33(5): 715-716.
  15. [15].
    郭欣煜，宋卓，许云，等．结直肠癌以阳虚阴结为核心病机辨治思路探讨[J].现代中西医结合杂志，2023，32(15)：2114-2118.
  16. [16].
    ZHANG T, YANG YF, HE B, et al. Efficacy and safety of Quxie Capsule in metastatic colorectal cancer: a double-blind randomized placebo controlled trial[J]. Chin J Integr Med, 2018, 24(3): 171-177.
  17. [17].
    张彤，杨宇飞. 祛邪胶囊治疗晚期结直肠癌疗效及安全性的随机对照临床试验[J]. 世界中医药，2021, 16(9): 1364-1371.
  18. [18].
    ZHANG T, XU Y, SUN LY, et al. Efficacy of Quxie Capsule in metastatic colorectal cancer: long-term survival update of a double-blind, randomized, placebo controlled trial[J]. Chin J Integr Med，2022, 28(11)：971-974.
  19. [19].
    EDGE SB. American Joint Committee on Cancer: AJCC cancer staging manual[M]. 7th ed. New York: Springer，2010：143-164.
  20. [20].
    DENG YY, ZHANG XY, ZHU PF, et al. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: a real-world study[J]. Front Oncol, 2023, 13: 1097911.
  21. [21].
    王慧. 中西医结合治疗左、右半结肠癌生存差异及中医证型分布研究[D]. 上海：上海中医药大学，2020.
  22. [22].
    RAVN S, HEIDE-JØRGENSEN U, CHRISTIANSEN CF, et al. Overall risk and risk factors for metachronous peritoneal metastasis after colorectal cancer surgery: a nationwide cohort study[J]. BJS Open, 2020, 4(2): 284-292.
  23. [23].
    CHRISTENSEN TD, PALSHOF JA, LARSEN FO, et al. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer[J]. Acta Oncol, 2018, 57(8): 1057-1062.
  24. [24].
    王磊，顾知恩，陈悦，等. 基于“屡攻屡补，以平为期”理论的阴阳攻积丸治疗晚期结直肠癌的中医学认识及临床依据[J]. 中医药临床杂志，2024, 36(4): 607-611.
  25. [25].
    GU Z, WANG L, MA JZ, et al. Conventional therapy combined with quxie capsule modulating gut microbiome in metastatic colorectal cancer patients with the third or above line setting: result from an investigator-initiated, open-label, single-arm, phase II study[J]. Integr Cancer Ther, 2024, 23: 15347354241280390.
  26. [26].
    宋卓，陈悦，翟嘉威，等. 基于网络药理学探讨大复方祛邪胶囊治疗结直肠癌的作用机制[J]. 世界中医药，2021, 16(9): 1349-1356.

قراءة النص الكامل

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website